← Back to patent-cliff list
Relugolix Combination
Tier C — Watch / tradeRelugolix Combination
Aska Pharmaceutical Co Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：GnRHR
Indications (approved)：子宫疾病, Endometriosis
Regional status
US
-
EU
-
China
-
Japan
Phase II
2023-08-17
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Relugolix Combination?
Approved indications include: 子宫疾病, Endometriosis.
When does the Relugolix Combination patent expire?
No public expiry year is available for Relugolix Combination yet; this page updates once verified.
How do I get a quote for Relugolix Combination intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02